Related references
Note: Only part of the references are listed.Cancer vaccines for established cancer: how to make them better?
Daniel M. Andrews et al.
IMMUNOLOGICAL REVIEWS (2008)
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen
Daniel E. Speiser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Raymond M. Wong et al.
INTERNATIONAL IMMUNOLOGY (2007)
Principles of adoptive T cell cancer therapy
Carl H. June
JOURNAL OF CLINICAL INVESTIGATION (2007)
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes
Pedro Romero et al.
JOURNAL OF IMMUNOLOGY (2007)
Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands
Rafael Solana et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma
Elissaveta Naumova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation
Javier Carrasco et al.
BLOOD (2006)
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide
Victor Appay et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Adoptive immunotherapy for cancer: building on success
L Gattinoni et al.
NATURE REVIEWS IMMUNOLOGY (2006)
In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire
WY Ho et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2006)
Programming CD8(+) T cells for effective immunotherapy
Christian S. Hinrichs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
CD8(+) T-cell memory in tumor immunology and immunotherapy
Christopher A. Klebanoff et al.
IMMUNOLOGICAL REVIEWS (2006)
Adoptive T cell therapy of solid cancers
KL Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Manufacturing and quality control of cell-based tumor vaccines: A scientific and a regulatory perspective
Thomas Hinz et al.
JOURNAL OF IMMUNOTHERAPY (2006)
CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype
JG Casado et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy
JH Zhou et al.
JOURNAL OF IMMUNOLOGY (2005)
Engineering T cells for cancer therapy
W Mansoor et al.
BRITISH JOURNAL OF CANCER (2005)
Optimum in vitro expansion of human antigen-specific CD8+ T cells for adoptive transfer therapy
M Montes et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients
C Maczek et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Understanding the generation and function of memory T cell subsets
A Lanzavecchia et al.
CURRENT OPINION IN IMMUNOLOGY (2005)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
L Gattinoni et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
JP Huang et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals
E Naumova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens
C Germeau et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Current developments of immunotherapy in the clinic
S Antonia et al.
CURRENT OPINION IN IMMUNOLOGY (2004)
Tumour escape: antitumour effectors too much of a good thing?
G Pawelec
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma
A Anichini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Cancer immunotherapy: A treatment for the masses
JN Blattman et al.
SCIENCE (2004)
Immunotherapy and immunoselection - tumour escape as the final hurdle
G Pawelec
FEBS LETTERS (2004)
Central memory and effector memory T cell subsets: Function, generation, and maintenance
F Sallusto et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Lessons from the study of T-cell differentiation in persistent human virus infection
V Appay et al.
SEMINARS IN IMMUNOLOGY (2004)
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen
C Lonchay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Expression of NK-associated receptors on cytotoxic T cells from melanoma patients:: a two-edged sword?
R Tarazona et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions
N Rufer et al.
BLOOD (2003)
Adoptive-cell-transfer therapy for the treatment of patients with cancer
ME Dudley et al.
NATURE REVIEWS CANCER (2003)
Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients:: Role of common γ-chain cytokines
A Anichini et al.
JOURNAL OF IMMUNOLOGY (2003)
Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy
K Matsui et al.
INTERNATIONAL IMMUNOLOGY (2003)
Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines
J Geginat et al.
BLOOD (2003)
Adoptive T cell therapy - immune monitoring and MHC multimers
C Yee
CLINICAL IMMUNOLOGY (2003)
Effective anti-tumor adoptive immunotherapy: utilization of exogenous IL-2-independent cytotoxic T lymphocyte clones
M Iwashiro et al.
INTERNATIONAL IMMUNOLOGY (2002)
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma
P Romero et al.
IMMUNOLOGICAL REVIEWS (2002)
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen
PG Coulie et al.
IMMUNOLOGICAL REVIEWS (2002)
Frequency of MART-1/MelanA and gp100/PMe117-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes
S Seiter et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
V Appay et al.
NATURE MEDICINE (2002)
Peptide-specific CD8+T-cell evolution in vivo:: Response to peptide vaccination with Melan-A/MART-I
E Jäger et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
PR Dunbar et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
